The UNC MTCC Program has selected a configuration of six Cores and three Pilot &Feasibility Project to synergize and accelerate the progress of molecular therapy research at UNC CH. The Administrative Core (Core A, R.C. Boucher, P.I.) will oversee and coordinate all aspects of the MTCC operation, including the operation of Core facilities and the selection and oversight of the Pilot &Feasibility Program. In addition, this Core will interface with other important activities on the UNC CH campus, including training and clinical trials networks. Each Core will provide novel and important services to the UNC CH molecular therapeutics community. The Vector Core (Core B, J. Beecham, P.I.) will provide new vectors (double-stranded, shuffled, chimeric AAV, high capacity adenoviral, paramyxovirus) and services (plasmid preparation). The Molecular Biology and Mouse Core (Core C, W. O'Neal, P.I.) will provide mice with CF like lung disease ((3ENaC and pENaC/CF mice) and shRNA technologies. The Imaging Core (Core D, C.W. Davis, P.I.) will provide a range of new imaging technologies, as well as histology and EM capabilities. The Correction Core (Core E, S.E. Gabriel, P.I.) will provide UNC CH investigators with a wide range of airway and G.I. assays to detect correction of CF defects both in in vivo and in vitro systems. The Cell Models Core (Core F, S. Randell, P.I.) will provide additional cell types to the MTCC community, e.g., airway and G.I. stem cells, as well as novel airway immortalized cell lines. The Cores will be supplemented by three Pilot &Feasibility Projects. P&F 7 (L. Ostrowski, P.I.), in collaboration with Drs. Olsen and Kafri, will explore the efficiency requirements for correcting with lentiviruses diseases characterized as "ciliopathies". P&F 8 (A. Asokan, P.I.), in collaboration with Dr. Samulski, will explore the targeting of G.I. epithelia, including stem cells, for CF mouse gut correction. P&F 9 (J. Olsen, P.I.) will, in collaboration with Dr. Grubb, test the efficiency of integrating vs. non-integrating EIAV lentiviral vectors in correcting the neonatal phenotype of the CF-like (3ENaC/AF508 CF mouse lung. The MTCC is complemented at UNC by an environment rich in basic science, translational research, and training that will guarantee maximal utilization of MTCC resources.

Public Health Relevance

Cystic fibrosis is the most common lethal genetic disease affecting Caucasian Americans. The efforts of the MTCC are dedicated towards developing gene therapy technologies designed to arrest or even cure this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK065988-09
Application #
8249137
Study Section
Special Emphasis Panel (ZDK1-GRB-1 (J2))
Program Officer
Mckeon, Catherine T
Project Start
2004-04-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
9
Fiscal Year
2012
Total Cost
$1,021,397
Indirect Cost
$331,264
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sesma, Juliana I; Weitzer, Clarissa D; Livraghi-Butrico, Alessandra et al. (2016) UDP-glucose promotes neutrophil recruitment in the lung. Purinergic Signal 12:627-635
Mitchel, Jennifer A; Antoniak, Silvio; Lee, Joo-Hyeon et al. (2016) IL-13 Augments Compressive Stress-Induced Tissue Factor Expression in Human Airway Epithelial Cells. Am J Respir Cell Mol Biol 54:524-31
Livraghi-Butrico, A; Grubb, B R; Wilkinson, K J et al. (2016) Contribution of mucus concentration and secreted mucins Muc5ac and Muc5b to the pathogenesis of muco-obstructive lung disease. Mucosal Immunol :
Button, Brian; Anderson, Wayne H; Boucher, Richard C (2016) Mucus Hyperconcentration as a Unifying Aspect of the Chronic Bronchitic Phenotype. Ann Am Thorac Soc 13 Suppl 2:S156-62
Cholon, Deborah M; Esther Jr, Charles R; Gentzsch, Martina (2016) Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Rev Precis Med Drug Dev 1:235-243
Yu, Dongfang; Davis, Richard M; Aita, Megumi et al. (2016) Characterization of Rat Meibomian Gland Ion and Fluid Transport. Invest Ophthalmol Vis Sci 57:2328-43
Dang, Hong; Gallins, Paul J; Pace, Rhonda G et al. (2016) Novel variation at chr11p13 associated with cystic fibrosis lung disease severity. Hum Genome Var 3:16020
Menachery, Vineet D; Yount Jr, Boyd L; Sims, Amy C et al. (2016) SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A 113:3048-53
Watson, Michael J; Lee, Shernita L; Marklew, Abigail J et al. (2016) The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Uses its C-Terminus to Regulate the A2B Adenosine Receptor. Sci Rep 6:27390
Blackmon, Richard L; Kreda, Silvia M; Sears, Patrick R et al. (2016) Diffusion-sensitive optical coherence tomography for real-time monitoring of mucus thinning treatments. Proc SPIE Int Soc Opt Eng 9697:

Showing the most recent 10 out of 92 publications